Aa861

Endocannabinoids - docosahexaenoyl ethanolamide (DHEA), eicosapentaenoyl Ethanolamide (EPEA) and N-arachidonoyl-L-alanine (NALA), antagonists of CB1 and VR1 (AM251, cay10448), antioxidants (NAC and GSH), and inhibitors of 5-LO (AA861, zileuton and ebselen) were obtained from Cayman Chemical (Ann Arbor, MI).

Patient tissue specimens were obtained from patients seen at Xiangyang No.1 People's Hospital and Jingzhou Central Hospital after signed informed consent as approved by Xiangyang No.1 People's Hospital Institutional Review Board and the Yangtze University Centralized Institutional Review Board. Gastric tumor and adjacent normal gastric tissues (at least 3 cm away from tumor) were removed during surgery. Patients’ clinicopathological features are presented in Supplementary Table S1. The patient inclusion criteria used in the study are for all gastric cancer patients eligible for surgery. Gastric cancer cell lines N87 and AGS were obtained from the Cell Bank of Shanghai Institute of Biological Science. Cell lines were authenticated using a 9‐short tandem repeat (STR) profile analysis. Cells were cultured in MEM medium supplemented with 10% FBS, 2 mM L‐glutamine, and 1% of penicillin‐streptomycin (Invitrogen) in a humidified incubator at 37℃ with 5% CO₂. Fluorouracil (5‐FU), cisplatin, LY294002, and U0126 were obtained from Selleckchem. Alox5 inhibitors zileuton and AA861 were obtained from Cayman Chemical. All compounds were reconstituted following the manufacturer's instructions and stored as frozen stocks at −20℃.